Document:

Unassociated Document

    Name
      of
      Investor:__________________

    

    Number
      of
      Shares: __________________

    BIOMETRX,
      INC.

    

    SECURITIES
      PURCHASE AGREEMENT

    

    

    THE
      SECURITIES REFERRED TO HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
      ACT
      OF 1933, AS AMENDED (THE “ACT”) OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY
      NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL
      REGISTERED UNDER THE ACT AND REGISTERED OR QUALIFIED UNDER SUCH LAWS, OR UNLESS
      THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE SATISFACTORY
      TO
      THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. THE
      SECURITIES BEING OFFERED BY THE COMPANY ARE SECURITIES AS THAT TERM HAS BEEN
      DEFINED IN THE ACT. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE ACT
      IN
      RELIANCE UPON THE EXEMPTION FROM REGISTRATION PROVIDED BY SECTION 4 (2) THEREOF
      AND ARE SUBJECT TO RESTRICTIONS ON TRANSFER. FURTHER, THESE SECURITIES MAY
      ONLY
      BE SOLD PURSUANT TO EXEMPTIONS FROM REGISTRATION OR QUALIFICATION IN THE VARIOUS
      STATES, AND MAY BE SUBJECT TO ADDITIONAL RESTRICTIONS ON TRANSFER IN SUCH
      JURISDICTIONS.

    

    

    AGREEMENT
      dated as of ______________, 2008, by and between bioMETRX, Inc. a Delaware
      corporation (the “Company”) having an address at 500 North Broadway, Jericho,
      New York 11753, and the person or entity whose signature appears at the end
      of
      this Agreement (the “Investor”).

    

    

    WITNESSETH:

    

    WHEREAS,
      the Company desires to sell up to an aggregate of 60 units (the “Units”) of the
      Company’s securities, each Unit consisting of 138,750 shares of the Company’s
      Common Stock, $.001 par value (the “Common Stock”) and 69,375 Common Stock
      Purchase Warrants exercisable at $1.00 per share (the “Warrants”) for $25,000
      per Unit to certain persons including the Investor, who are “accredited
      investors” within the meaning of Rule 501(a) adopted under the Securities Act of
      1933 (the “Act”). The minimum purchase is one Unit at $25,000; and

    

    WHEREAS,
      the Investor wishes, pursuant to the terms and conditions hereinafter set forth,
      to purchase the number of Units set forth on the signature page hereof.

    

    WHEREAS,
      Investor acknowledges receipt of the Confidential Private Placement Memorandum,
      dated April __, 2008 (the “Memorandum”), delivered to Investor in connection
      with the Offering. Capitalized terms used but not defined herein shall have
      the
      meanings given in the Memorandum.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    NOW
      THEREFORE, in consideration of the premises, and the respective representations
      and warranties hereinafter set forth, the Company and the Investor agree as
      follows:

    

    1. SUBSCRIPTION

    

    The
      Investor, intending to be legally bound, hereby irrevocably subscribes for
      and
      agrees to purchase from the Company the number of Units set forth on the
      signature page hereof. Subscription payments should be made payable to
“bioMETRX, Inc.” and should be delivered, together with two executed and
      properly completed copies of the Securities Purchase Agreement, to the Escrow
      Agent, Sommer & Schneider LLP 595 Stewart Ave. Suite 710 Garden City, New
      York 11753 Attention: Joel C. Schneider, Esq. If the subscription is not
      accepted in whole or in part by the Company, the full or ratable amount, as
      the
      case may be, of any subscription payment received will be promptly refunded
      to
      the subscriber without deduction therefore or interest thereon.

    

    The
      Units
      are being offered on a “best efforts $500,000 minimum” basis by various members
      of management and employees of the Company. Accordingly, until the minimum
      offering amount is received by the Escrow Agent no closing will occur. Once
      the
      minimum offering amount has been received and accepted by the Company we will
      have a first closing. .After the first closing, the Company may conduct closings
      at their sole discretion and immediately accept subscriptions and funds.
      Regardless of whether all of the Units have been sold, the Offering will
      terminate on ______, 2008, unless extended, in the Company’s sole discretion,
      for a period of up to sixty (60) days. In a best efforts offering there is
      no
      assurance that all or any part of the Units will be sold. No commissions or
      other similar compensation will be paid in connection with the sale of the
      Shares by the Company’s management and its employees. 

    

    2. PURCHASE
      AND CLOSING

    

    
      	 	
              2.1

            	
              Issuance
                and Sale of Units

            

    

    

    Upon
      the
      terms and subject to the conditions of this Agreement, at the first closing
      and
      all subsequent closings the Company shall issue and sell to the Investor, and
      the Investor shall purchase from the Company, in lawful money of the United
      States, the number of Units subscribed for hereunder for the aggregate purchase
      price calculated at the rate of $ 25,000 per Unit (the “Purchase Price”). The
      offer and sale of the Units are being effected in accordance with and in
      reliance on the provisions of Rule 506 under Regulation D under the Act.

    
      

      
        	 	
                2.2

              	
                
                  Closing

                

              

      

      
      

    

    Promptly
      upon execution and delivery of this Agreement by the Company and the
      Investor:

    

    (a) The
      Investor shall deliver to the Company:

    

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

       

    

    
      	 	
              (i)

            	
              two
                executed copies of this Agreement (or a photocopy or facsimile thereof);
                and

            

    

    

    
      	 	
              (ii)

            	
              payment
                of the full Purchase Price by certified check or money order made
                payable
                to the Company.

            

    

    

    (b) The
      Company shall deliver to the Investor:

    

    
      	 	
              (i)

            	
              an
                executed copy of this Agreement;

            

      	 	 	 

      	 	
              (ii)

            	
              a
                stock certificate representing the numbers of shares of Common Stock
                contained in the Units purchased hereunder, registered in the name
                of the
                Investor; and

            

      	 	 	 

      	 	
              (iii)

            	
              a
                warrant certificate representing the number of Warrants contained
                in the
                Units purchased hereunder, registered in the name of the
                Investor. 

            

    

     

    Promptly
      after the first closing and all subsequent closings the Company shall deliver
      the Units to the Investor.

     

    3. INVESTOR
      REPRESENTATIONS AND WARRANTIES.

    

    The
      Investor hereby acknowledges, represents and warrants to, and agrees with,
      the
      Company as follows:

    

    3.1 The
      Investor is acquiring the Units for its own account as principal, for investment
      purposes only, and not with a view to, or for, resale, distribution or
      fractionalization thereof, in whole or in part, and no other person except
      the
      Investor’s corporate parent has a direct or indirect beneficial interest in such
      Units;

    

    3.2 The
      Investor acknowledges its understanding that the offering and sale of the Shares
      is intended to be exempt from registration under the Act by virtue of Section
      4(2) of the Act and the provisions of Regulation D thereunder. In furtherance
      thereof, the Investor represents and warrants to and agrees with the Company
      as
      follows:

    

    
      	 	
              (a)

            	
              the
                Investor has the financial ability to bear the economic risk of its
                investment, has adequate means for providing for its current needs
                and
                personal contingencies and has no need for liquidity with respect
                to its
                investment in the Company;

            

      	 	 	 

      	 	
              (b)

            	
              if
                the Investor is a natural person,

            

    

    
      	 	 	 	 

      	 	 	
              (i)

            	
              his
                net worth, individually or jointly with his or her spouse, exceeds
                $1,000,000 (inclusive of the value of home, home furnishings and
                automobiles); or

            

    

    

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    
      	 	 	 

      	 	
              (ii)

            	
              his
                personal income exceeded $200,000 in 2006 and 2007 and reasonably
                expects
                that his or her personal income will exceed $200,000 in 2008 (or
                whose
                joint net income with that of his or her spouse exceeds $300,000
                for the
                relevant periods);

            

    

    

    
      	 	
              (c)

            	
              if
                the Investor is an entity (i.e., a corporation, partnership, trust
                or
                estate), each of the equity owners meet the requirements of either
                category (b)(i) or category (b)(ii) above and was not specifically
                formed
                to acquire the Units subscribed for herein;
                or

            

    

    

    
      	 	
              (d)

            	
              the
                Investor is a corporation, trust, estate benefit plan, partnership
                other
                entity, which comes within a category of “accredited investor” as that
                term is defined in Rule 501(a) of Regulation D under the Act (17
                C.F.R.
                230.501(a));

            

    

    

    3.3 The
      Investor:

    

    
      	 	
              (a)

            	
              has
                not been furnished with any documents from the Company other than
                this
                Securities Purchase Agreement, and is making this investment solely
                on the
                reputation of management;

            

    

    

    
      	 	
              (b)

            	
              has
                not been furnished with any oral representation or oral information
                in
                connection with the offering of the Units which is not contained
                in the
                Documents; and

            

    

    

    
      	 	
              (c)

            	
              has
                determined that the Units are a suitable investment and that at this
                time
                the Investor could bear a complete loss of its
                investment;

            

    

    

    3.4 The
      Investor is not relying on the Company with respect to economic considerations
      involved in this investment.

    

    3.5 The
      Investor represents, warrants and agrees that it will not sell or otherwise
      transfer the Units unless registered under the Act or in reliance upon an
      exemption therefrom, and fully understands and agrees that it must bear the
      economic risk of its purchase for an indefinite period of time because, among
      other reasons, the Units or underlying securities have not been registered
      under
      the Act or under the securities laws of certain states and, therefore, cannot
      be
      resold, pledged, assigned or otherwise disposed of unless they are subsequently
      registered under the Act and under the applicable securities laws of such states
      or an exemption from such registration is available. The Investor further
      understands that sales or transfers of the Units or underlying securities are
      restricted by the provisions of state securities laws.

    

    3.6 The
      person signing this Securities Purchase Agreement on behalf of such entity
      has
      been duly authorized by such entity to do so.

    

    3.7 No
      representation or warranties have been made to the Investor by the Company,
      or
      any officer, employee, agent, affiliate or subsidiary of the Company, other
      than
      the representations of the Company herein.

    

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

       

    

    3.8 The
      execution and delivery by the Investor of, and the performance by the Investor
      of its obligations under this Agreement in accordance with its terms will not
      contravene any provision of applicable law or the charter documents of the
      Investor or any agreement or other instrument binding upon the Investor, or
      any
      judgment, order or decree of any governmental body, agency or court having
      jurisdiction over the Investor, and no consent, approval, authorization or
      order
      of, or qualification with, any governmental body or agency is required for
      the
      performance by the Investor of its obligations under such Agreements in
      accordance with their respective terms.

    

    3.9 If
      the
      Investor is a corporation, the Investor has been duly organized, is validly
      existing and is in good standing under the laws of its state of incorporation.
      The Investor has full power and authority (corporate or otherwise) to enter
      into
      this Agreement and this Agreement has been duly and validly authorized, executed
      and delivered by the Investor and are valid and binding obligations of the
      Investor, enforceable against the Investor in accordance with their respective
      terms, except as such enforcement may be limited by the United States Bankruptcy
      Code, laws effecting creditors rights, generally and general equitable
      principles.

    

    3.10 The
      Investor represents, warrants and agrees that as long as the Shares are
      restricted the Investor will not, directly or indirectly, or through one or
      more
      intermediaries, maintain any short position in the Company’s Common
      Stock.

    

    3.11 The
      foregoing representations, warranties and agreements shall survive the
      Closing.

    

    4. INVESTOR
      AWARENESS.

    

    The
      Investor acknowledges, represents, agrees and is aware that:

    

    4.1 No
      Federal or state agency has passed on the Units or made any finding or
      determination as to the fairness of this investment;

    

    4.2 There
      are
      substantial risks incident to the purchase of Units; 

    

    4.3 The
      investment in the Company is an illiquid investment and the Investor must bear
      the economic risk of investment in the Units for an indefinite period of
      time;

    

    4.4 There
      are
      substantial restrictions on transferability of the Units;

    

    4.5 The
      foregoing acknowledgments, representations, warranties and agreements shall
      survive the Closing.

    

    5. INDEMNITY. 

     

    The
      Investor agrees to indemnify and hold harmless the Company and each other
      person, if any, who controls it within the meaning of Section 15 of the Act
      against any and all loss, liability, claim, damage and expense whatsoever
      (including, but not limited to, any and all expenses whatsoever reasonably
      incurred in investigating, preparing for or defending against any litigation
      commenced or threatened or any claim whatsoever) arising out of or based upon
      any false representation or warranty or breach or failure by the Investor to
      comply with any covenant or agreement made by the Investor herein.

    

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

    

    6. COMPANY
      REPRESENTATIONS AND WARRANTIES.

    

    The
      Company hereby acknowledges, represents and warrants to, and agrees with the
      Investor (which representations and will be true and correct as of the date
      of
      the Closing as if the Agreement were made on the date of Closing) as
      follows:

    

    6.1 The
      Company has been duly organized, is validly existing and is in good standing
      under the laws of the State of Florida. The Company has full corporate power
      and
      authority to enter into this Agreement, and once executed and delivered by
      the
      Company constitutes a valid and binding obligation of the Company, enforceable
      against the Company in accordance with its terms, except as such enforcement
      may
      be limited by the United States Bankruptcy Code, laws effecting creditors
      rights, generally and general equitable principles.

    

    6.2 This
      Securities Purchase Agreement has been duly executed and delivered by the
      Company. The execution, delivery and performance by the Company of the
      Securities Purchase Agreement has been duly authorized by all requisite
      corporate action of the Company and each, upon execution and delivery thereof
      by
      the Company will constitute the legal, valid and binding obligation of the
      Company, enforceable against the Company in accordance with its respective
      terms.

    

    6.3 The
      issuance and delivery of the Common Stock have been duly authorized by all
      requisite corporate action of the Company and, when so issued, sold and
      delivered, the Shares will be duly executed, issued and delivered and will
      constitute fully paid, validly issued and nonassessable Shares of the Company,
      free and clear of all liens encumbrances and claims whatsoever (except as
      arising under applicable securities laws) and, in each case, will not be subject
      to preemptive or any other similar rights of the shareholders of the Company,
      or
      others which rights shall not have been waived or exercised prior to
      Closing.

    

    6.4 Subject
      to the performance by the Investor of its obligations under this Agreement
      and
      the accuracy of the representations and warranties of the Investor, the offering
      and sale of the Shares will be exempt from the registration requirements of
      the
      Act.

    

    6.5 The
      execution and delivery by the Company of, and the performance by the Company
      of
      its obligations under this Agreement in accordance with the terms of this
      Agreement, will not contravene any provision of applicable law or the charter
      documents of the Company or any agreement or other instrument binding upon
      the
      Company, or any judgment, order or decree of any governmental body, agency
      or
      court having jurisdiction over the Company, and no consent, approval,
      authorization or order of, or qualification with, any governmental body or
      agency is required for the performance by the Company of its obligations under
      this Agreement in accordance with the terms of this Agreement.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

       

    

    6.6 All
      of
      the outstanding shares of capital stock of the Company have been duly authorized
      and validly issued and are fully paid, non-assessable and free of preemptive
      or
      similar rights. As of April 15, 2008, the Company has 100,000,000 shares of
      Common Stock authorized, of which aprroximately 19,500,000 shares of Common
      Stock are issued and outstanding.. 

    

    6.7 The
      Company is not in violation of its charter or bylaws and is not in default
      in
      the performance of any bond, debenture, note or any other evidence of
      indebtedness or any indenture, mortgage, deed of trust, license, contract,
      lease
      or other instrument to which the Company is a party or by which it is bound,
      or
      to which any of the property or assets of the Company is subject, except such
      as
      have been waived or which would not have, singly or in the aggregate, a material
      adverse effect on the Company, taken as a whole.

    

    6.8 There
      is
      no material litigation or governmental proceeding pending, or to the knowledge
      of the Company, threatened against, or involving the property or the business
      of
      the Company, or, to the best knowledge of the Company which would adversely
      affect the condition (financial or otherwise), business, prospects or results
      of
      operations of the Company, taken as a whole.

    

    6.9 The
      foregoing representations, warranties and agreements shall survive the
      Closing.

    

    6.10 For
      so
      long as any Shares held by Investor remain outstanding, the Company covenants
      and agrees with the Investor that:

    

    (a) The
      Company will undertake to use its best efforts to continue to have its Common
      Stock quoted on the OTC Bulletin Board; and

    

    (b) Except
      as
      expressly set forth in Section 7 below, the Company will not issue stop transfer
      instructions to its transfer agent in regard to the Units.

    

    7. MISCELLANEOUS.

    

    7.1 Modification. Neither
      this Agreement nor any provisions hereof shall be modified, discharged or
      terminated except by an instrument in writing signed by the party against whom
      any waiver, change, discharge or termination is sought.

    

    7.2 Notices.
      Any
      notice, demand or other communication which any party hereto may be required,
      or
      may elect, to give to anyone interested hereunder shall be sufficiently given
      if
      (a) deposited, postage prepaid, in a United States mail letter box, registered
      or certified mail, return receipt requested, addressed to such address as may
      be
      given herein, or (b) delivered personally at such address.

    

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

       

    

    7.3 Counterparts. This
      Agreement may be executed through the use of separate signature pages or in
      any
      number of counterparts, and each of such counterparts shall, for all purposes,
      constitute one agreement binding on all the parties, notwithstanding that all
      parties are not signatories to the same counterpart.

    

    7.4 Binding
      Effect.
      Except
      as otherwise provided herein, this Agreement shall be binding upon and inure
      to
      the benefit of the parties and their heirs, executors, administrators,
      successors, legal representatives and assigns. If the undersigned is more than
      one person, the obligation of the Investor shall be joint and several, and
      the
      agreements, representations, warranties and acknowledgments herein contained
      shall be deemed to be made by and be binding upon each such person and his
      heirs, executors, administrators and successors.

    

    7.5 Entire
      Agreement. This
      instrument contains the entire agreement of the parties, and there are no
      representations, covenants or other agreements except as stated or referred
      to
      herein.

    

    7.6 Assignability.
      This
      Agreement is not transferable or assignable by the Investor except as may be
      provided herein.

    

    7.7 Applicable
      Law.
      This
      Agreement shall be governed and construed under the laws of the State of New
      York.

    

    8. REGULATORY
      NOTICES.

    

    THESE
      MATERIALS HAVE NOT BEEN REVIEWED BY THE SECURITIES EXCHANGE COMMISSION, THE
      ATTORNEY GENERAL OF ANY STATE, OR ANY OTHER REGULATORY AUTHORITY PRIOR TO THEIR
      ISSUANCE AND USE. NO ATTORNEY GENERAL FROM ANY STATE HAS PASSED ON OR ENDORSED
      THE MERITS OF THIS OFFERING. ANY REPRESENTATION TO THE CONTRARY IS
      UNLAWFUL.

    

    

    

    [EXECUTION
      PAGES FOLLOW]

    

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    9. EXECUTION.

    

    9.1 Investor.
      The
      Investor has executed this Securities Purchase Agreement on this _____ day
      of
      _________________, 2008.

    

    Number
      of
      Shares to be
      purchased:                         
     

    

    Price
      per
      Share:  $25,000      

    

    Total
      Purchase Price: $                  
              

    

    INSTRUCTION:
      (The execution pages and acknowledgment for subscribers follows this
      page.)

    

    9.2 The
      Company.        

    

    Accepted
      this ____ day of ___________, 2008.

    

    
      	 	 	bioMETRX,
              Inc.
	 	 
	 
 	 
 	 
 
	 	By:  	 
	 	
              
Mark
              Basile, Chief Executive Officer
	 	 

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    EXECUTION

    

    Please
      execute this Securities Purchase Agreement by completing the appropriate section
      below.

    

    1. If
      the
      prospective investor is an INDIVIDUAL, complete the following:

    

                                                                                                                                          
 

    Signature
      of Proposed Investor

    

    
                                                                                                                                            
 

    

    Name
      (Please type or print)

    

    
                                                                                                                                            
 

    

    Signature
      of Spouse or Co-Investor if funds are to be invested 

    as
      joint
      tenants, tenants by the entirety or community property.

    

    
                                                                                                                                            
 

    

    Name
      (Please type or print)

    

    Address:
      _____________________________________ ___   

    

    2. If
      the
      prospective investor is a CORPORATION, complete the following:

    

    The
      Investor hereby represents, warrants and covenants that the Investor has been
      duly authorized by all requisite action on the part of the prospective investor
      listed below to enter into this Securities Purchase Agreement and Investment
      Representation and, further, that the prospective investor has all requisite
      authority to enter into such Agreement.

    

    The
      Investor represents and warrants that each of the above representations or
      agreements or understandings set forth herein applies to that prospective
      investor and that he has authority under the charter, by-laws and resolutions
      of
      the Board of Directors of such prospective investor to execute this Agreement.
      Such officer encloses a true copy of the charter, the by-laws and the
      resolutions of the Board of Directors authorizing the execution of this
      Securities Purchase Agreement and Investment Representation.

    

    
                                                                                                                                            
 

    

    Name
      of
      Corporation (Please type or print)

    

    Address:
      _________________________________________

    

    By:                                                                                                           

           

    
                        
        Name of
        Signatory:                                                                               
               

      

    

    Title:                                                                                                       

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

       

    

    3. If
      the
      prospective investor is a PARTNERSHIP, complete the following:

    

    The
      Investor hereby represents, warrants and covenants that the Investor is a
      general partner of the prospective investor named below, has been duly
      authorized by the prospective investor to acquire the Shares, the prospective
      investor has all requisite authority to enter into this Securities Purchase
      Agreement and Investment Representation and set forth below are the names of
      all
      Partners of the prospective investor.

    

    The
      Investor represents and warrants that each of the above representations or
      agreements or understandings set forth herein applies to that prospective
      investor and he is authorized by such prospective investor to execute this
      Securities Purchase Agreement and Investment Representation. Such Partner
      encloses a true copy of the Partnership Agreement of said prospective
      investor.

    

    
                                                                                                                                            
 

    

    Name
      of
      Partnership (Please type or print)

    

    Address:
      _________________________________________

     

    By:                                                                                                           

    
                        
      Name of
      Signatory:                                                                               

             

      Title:                                                                                                        

    

     

    Names
      of
      Partners:

    
                                                                                                                                              

       

    

    
                                                                                                                                              

       

    

    
                                                                                                                                             

    

    

    4. If
      the
      prospective investor is a TRUST, complete the following:

    

    The
      Investor hereby represents, warrants and covenants that he as Trustee is duly
      authorized by the terms of the trust instrument (“Trust Instrument”) for the
      prospective investor set forth below to enter into this Securities Purchase
      Agreement and Investment Representation.

    

    The
      Investor, as trustee, executing this Securities Purchase Agreement and
      Investment Representation on behalf of the prospective investor represents
      and
      warrants that each of the above representations or agreements or understandings
      set forth herein applies to that prospective investor and he is authorized
      by
      such prospective investor to execute this Securities Purchase Agreement and
      Investment Representation. Such trustee encloses a true copy of the Trust
      Instrument of said prospective investor.

    

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

       

    

    
                                                                                                                                             

    

    Name
      of
      Trust (Please type or print)

    
      

      Address:
        _________________________________________

       

      By:                                                                                                           

      
                        
        Name of
        Signatory:                                                                               

               

        Title:                                                                                                        

      

    

    

    5. If
      the
      prospective investor is an ESTATE, complete the following:

    

    The
      Investor hereby represents, warrants and covenants that he is duly authorized
      by
      the terms of the Will, and/or Codicil of the prospective investor named below
      to
      enter into this Securities Purchase Agreement and Investment Representation
      and
      that the prospective investor has all requisite authority to enter into such
      Agreement, pursuant to Letters Testamentary issued by a court of appropriate
      jurisdiction.

    

    The
      Investor represents and warrants that each of the above representations or
      agreements or understandings set herein applies to that prospective investor
      and
      he is authorized by the terms of the Will and/or Codicil of such prospective
      investor to execute this Securities Purchase Agreement and Investment
      Representation. Such Executor encloses a true copy of the Will, including any
      codicils thereto and Letters Testamentary issued by a court of appropriate
      jurisdiction, and any and all amendments thereto, of said prospective
      investor.

     

    
                                                                                                                                             

    

    Name
      of
      Estate (Please type or print)         

    
      
        

        Address:
          _________________________________________

         

        By:                                                                                                           

        
                        
          Name of
          Signatory:                                                                               

                 

          Title:                                                                                                        

        

      

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

    INDIVIDUAL
      ACKNOWLEDGMENT

    

     

    STATE
      OF
      ____________________ )

                              
      ) ss.:

    COUNTY
      OF
      __________________ )

    

    On
      the
      ______ day of _____________, 2008, before me personally came
      ________________________________________, known to me to be the individual(s)
      described in and who acknowledged the foregoing instrument and swore and
      acknowledged that (he)(she)(they) executed the same as (his)(her)(their) free
      act and deed.

    

    
      
        	 	
                _________________________________

              
	 	
                Notary
                  Public

              
	 	 
	 	
                My
                  commission expires:
                  ____________

              

      

    

     

    

    PARTNERSHIP
      ACKNOWLEDGMENT

    

    STATE
      OF
      ____________________ )

    
                                
        ) ss.:
COUNTY
      OF
      __________________ )

    

    On
      the
      ______ day of _____________, 2008, before me personally appeared the above-named
      general partner of _______________________________________________, who swore
      and acknowledged that being authorized and directed to do so (s)he did sign
      the
      foregoing instrument, and that the same is the free act and deed of said
      Partnership and the free act and deed personally of such general
      partner.

    

    

      
        	 	
                _________________________________

              
	 	
                Notary
                  Public

              
	 	 
	 	
                My
                  commission expires:
                  ____________

              

      

    

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

     

    CORPORATE
      ACKNOWLEDGMENT

    

    

    STATE
      OF
      ____________________ )

    
                                
        ) ss.:
COUNTY
      OF
      __________________ )

    

    ________________________________,
      the corporation that executed the foregoing instrument, who, being duly sworn,
      acknowledged that (s)he resides at _____________________
      __________________________________________, that (s)he knows the seal of said
      corporation, that the seal affixed to said instrument is such corporate seal;
      that it was so affixed by the order of the Board of Directors of said
      corporation; and that (s)he signed his name there to by like order.

    

    
      

        
          	 	
                  _________________________________

                
	 	
                  Notary
                    Public

                
	 	 
	 	
                  My
                    commission expires:
                    ____________

                

        

      

    

     

    ESTATE
      OR TRUST ACKNOWLEDGMENT

    

    STATE
      OF
      ____________________ )

    
                                
        ) ss.:
COUNTY
      OF
      __________________ )

    

    On
      the
      _______ day of _____________________, 2008, before me personally came
      ___________________________________________, [the executor of the Last Will
      and
      Testament of ______________________________________________________, deceased]
      or [administrator of the good, chattels and credits
      _________________________________ of ___________________________, deceased]
      or
      [trustee ________________________________ of
      __________________________________________, deceased] residing in
      ______________________________________________________, and known to me to
      be
      the person described in and who executed the foregoing instrument and
      acknowledged that (s)he executed the same as such [executor] or [administrator]
      or [trustee].

    

    
      

        
          	 	
                  _________________________________

                
	 	
                  Notary
                    Public

                
	 	 
	 	
                  My
                    commission expires:
                    ____________

                

        

      

    

    
 

    
      
        
        

      

      
        14Unassociated Document

    THIS
      WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN
      REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"),
      OR ANY STATE SECURITIES LAW, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED,
      PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF OR EXERCISED UNLESS (i) A
      REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES
      LAWS SHALL HAVE BECOME EFFECTIVE WITH REGARD THERETO, OR (ii) AN EXEMPTION
      FROM
      REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS
      IS
      AVAILABLE IN CONNECTION WITH SUCH OFFER, SALE OR TRANSFER.

    

    AN
      INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST
      RELY
      ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.
      

    

    

    Warrant
      to Purchase

    
      
        	
                ___,000,000 shares

              	
                Warrant
                  Number ____

              

      

    Warrant
      to Purchase Common Stock

    of

    BIOMETRX,
      INC.

    

    THIS
      CERTIFIES that ____________________or
      any
      subsequent holder hereof ("Holder") has the right to purchase from BIOMETRX,
      INC.,
      a
      Delaware corporation, (the
      "Company"), up __________ fully paid and nonassessable shares, of the Company's
      common stock, $0.01 par value per share ("Common Stock"), subject to adjustment
      as provided herein, at a price equal to the Exercise Price as defined in Section
      3 below, at any time during the Term (as defined below). 

    

    Holder
      agrees with the Company that this Warrant to Purchase Common Stock of the
      Company (this “Warrant” or this “Agreement”) is issued and all rights hereunder
      shall be held subject to all of the conditions, limitations and provisions
      set
      forth herein.

    

    1. Date
      of Issuance and Term.

    

    This
      Warrant shall be deemed to be issued on _________, 2008 (“Date of Issuance”).
      The term of this Warrant begins on the Date of Issuance and ends at 5:00 p.m.,
      New York City time, on the date that is five (5) years after the Date of
      Issuance (the “Term”). This Warrant was issued as part of the Units of the
      Company to the Holder pursuant to the terms of the Securities Purchase Agreement
      (“Securities Purchase Agreement”) by and between the Company and Holder dated on
      or about April __, 2008.

    

    Notwithstanding
      anything to the contrary herein, the applicable portion of this Warrant shall
      not be exercisable during any time that, and only to the extent that, the number
      of shares of Common Stock to be issued to Holder upon such exercise, when added
      to the number of shares of Common Stock, if any, that the Holder otherwise
      beneficially owns (outside of this Warrant, and not including any other warrants
      or securities of Holder’s having a provision substantially similar to this
      paragraph) at the time of such exercise, would exceed 4.99% of the number of
      shares of Common Stock then outstanding, as determined in accordance with
      Section 13(d) of the Exchange Act (the “4.99% Beneficial Ownership Limitation”).
      The 4.99% Beneficial Ownership Limitation shall be conclusively satisfied if
      the
      applicable Exercise Notice includes a signed representation by the Holder that
      the issuance of the shares in such Exercise Notice will not violate the 4.99%
      Limitation, and the Company shall not be entitled to require additional
      documentation of such satisfaction.

    

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

       

    

    Notwithstanding
      the above, in the event that the Company receives any purchase, tender or
      exchange offer or any offer to enter into a merger with another entity whereby
      the Company shall not be the surviving entity (an “Offer”), then “4.99%” shall
      be automatically revised immediately after such offer to read “9.99%” each place
      it occurs in this Section 1. In addition, the 4.99% Beneficial Ownership
      Limitation provisions of this Section 1 may be waived by such Holder, at the
      election of such Holder, upon not less than 61 days’ prior notice to the
      Company, to change the 4.99% Beneficial Ownership Limitation to 9.99% of the
      number of shares of the Common Stock outstanding immediately after giving effect
      to the issuance of shares of Common Stock upon exercise of the Warrants held
      by
      the Holder and the provisions of this Section 1 shall continue to apply. The
      limitations on exercise set forth in this subsection are referred to as the
      “Beneficial Ownership Limitations.” Upon such a change by a Holder of the
      Beneficial Ownership Limitations from such 4.99% limitation to such 9.99%
      limitation, the Beneficial Ownership Limitations may not be further waived
      by
      such Holder. The provisions of this paragraph shall be construed and implemented
      in a manner otherwise than in strict conformity with the terms of this Section
      1
      to correct this paragraph (or any portion hereof) which may be defective or
      inconsistent with the intended Beneficial Ownership Limitation herein contained
      or to make changes or supplements necessary or desirable to properly give effect
      to such limitation. 

    

    Notwithstanding
      the above, Holder shall retain the option to either exercise or not exercise
      its
      option(s) to acquire Common Stock pursuant to the terms hereof after an Offer,
      and, in the event of a cash exercise following a tender offer, the Exercise
      Price per share that would otherwise be due shall instead be offset against
      the
      tender price per share to be received by the Holder, provided, however, that
      in
      the event a tender offer is not completed, Holder, at its option may either
      (i)
      complete any Exercise that was initiated after the Offer by promptly paying
      to
      the Company the Exercise Price that would have been due at the time the Warrant
      was Exercised, or (ii) cancel such exercise by providing written notice to
      the
      Company, in which case such Exercise shall be deemed void ad
      initio.

    

     Maximum
      Exercise of Rights.
      In the
      event the Holder notifies the Company that the exercise of the rights described
      herein would result in the issuance of an amount of common stock of the Company
      that would exceed the maximum amount that may be issued to a Holder calculated
      in the manner described above, then the issuance of such additional shares
      of
      common stock of the Company to such Holder will be deferred in whole or in
      part
      until such time as such Holder is able to beneficially own such common stock
      without exceeding the maximum amount set forth calculated in the manner
      described in herein. The determination of when such common stock may be issued
      shall be made by each Holder as to only such Holder. 

    

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

       

    

    2. Exercise.

    

    (a)
      Manner of Exercise. During
      the Term, this
      Warrant may be exercised as to all or any lesser number of full shares of Common
      Stock covered hereby (the “Warrant Shares” or the “Shares”) upon surrender of
      this Warrant, with the Exercise Form attached hereto as Exhibit
      A
      (the
“Exercise Form”) duly completed and executed, together with the full Exercise
      Price (as defined below, which may be satisfied by either a Cash Exercise or
      a
      Cashless Exercise, as each is defined below) for each share of Common Stock
      as
      to which this Warrant is exercised, at the office of the Company, bioMETRX,
      Inc.; 500
      North
      Broadway, Suite 204; Jericho, NY 11753; Phone: 516-937-2828; Fax:
      516-937-2880, or
      at
      such other office or agency as the Company may designate in writing, by
      overnight mail, with an advance copy of the Exercise Form sent to the Company
      and its Transfer Agent by facsimile (such surrender and payment of the Exercise
      Price hereinafter called the "Exercise” of this Warrant).

     

    (b)
      Date of Exercise. The
      "Date
      of Exercise" of the Warrant shall be defined as the date that the advance copy
      of the completed and executed Exercise Form is sent by facsimile to the Company,
      provided that the original Warrant and Exercise Form are received by the Company
      and the Exercise Price is satisfied, each as soon as practicable thereafter.
      Alternatively, the Date of Exercise shall be defined as the date the original
      Exercise Form is received by the Company, if Holder has not sent advance notice
      by facsimile. 

    

    (c)
      Delivery of Common Stock Upon Exercise.
      Within
      three (3) business days after any Date of Exercise (the "DELIVERY PERIOD"),
      the
      Company shall issue and deliver (or cause its Transfer Agent so to issue and
      deliver) in accordance with the terms hereof to or upon the order of the Holder
      that number of shares of Common Stock (“Exercise Shares”) for the portion of
      this Warrant converted as shall be determined in accordance herewith. Upon
      the
      Exercise of this Warrant or part thereof, the Company shall, at its own cost
      and
      expense, take all necessary action, including obtaining and delivering, an
      opinion of counsel to assure that the Company's transfer agent shall issue
      stock
      certificates in the name of Holder (or its nominee) or such other persons as
      designated by Holder and in such denominations to be specified at exercise
      representing the number of shares of common stock issuable upon such exercise.
      The Company warrants that no instructions other than these instructions have
      been or will be given to the transfer agent of the Company's Common Stock and
      that, unless waived by the Holder, the Exercise Shares will be free-trading,
      and
      freely transferable, and will not contain a legend restricting the resale or
      transferability of the Exercise Shares if the Unrestricted Conditions (as
      defined below) are met.

    

    (d) Delivery
      Failure. In
      addition to any other remedies which may be available to the Holder, in the
      event that the Company fails for any reason to effect delivery of the Exercise
      Shares by the end of the Delivery Period (a “Delivery Failure”), the Holder will
      be entitled to revoke all or part of the relevant Notice of Exercise by delivery
      of a notice to such effect to the Company whereupon the Company and the Holder
      shall each be restored to their respective positions immediately prior to the
      delivery of such notice, except that the liquidated damages described above
      shall be payable through the date notice of revocation or rescission is given
      to
      the Company.

    

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

       

    

    (e)
       Legends. 

    

    (i)
      Restrictive
      Legend.
      The
      Holder understands that the Warrant and, until such time as Exercise Shares
      have
      been registered under the 1933 Act as contemplated by the Registration Rights
      Agreement or otherwise may be sold pursuant to Rule 144 or Rule 144(k) under
      the
      1933 Act without any restriction as to the number of securities as of a
      particular date that can then be immediately sold, the Exercise Shares may
      bear
      a restrictive legend in substantially the following form (and a stop-transfer
      order may be placed against transfer of the certificates for such
      securities):

    

    "The
      securities represented by this certificate have not been registered under the
      Securities Act of 1933, as amended, or applicable state securities laws. The
      securities may not be sold, transferred or assigned in the absence of an
      effective registration statement for the securities under said Act, or an
      opinion of counsel, in form, substance and scope reasonably satisfactory to
      counsel to the Company, that registration is not required under said Act or
      unless sold pursuant to Rule 144 under said Act."

    

    (ii)
      Removal
      of Restrictive Legends.
      Certificates evidencing the Exercise Shares shall not contain any legend
      restricting the transfer thereof (including the legend set forth above in
      subsection 2(e)(i)): (i) while a registration statement (including the
      Registration Statement) covering the resale of such security is effective under
      the Securities Act, or (ii) following any sale of such Exercise Shares pursuant
      to Rule 144, or (iii) if such Exercise Shares are eligible for sale under Rule
      144(k), or (iv) if such legend is not required under applicable requirements
      of
      the Securities Act (including judicial interpretations and pronouncements issued
      by the staff of the Commission) (collectively, the “Unrestricted Conditions”).
      The Company shall cause its counsel to issue a legal opinion to the Company’s
      transfer agent promptly after the Effective Date if required by the Company’s
      transfer agent to effect the issuance of Exercise Shares without a restrictive
      legend or removal of the legend hereunder. If the Unrestricted Conditions are
      met at the time of issuance of Exercise Shares, then such Exercise Shares shall
      be issued free of all legends. The Company agrees that following the Effective
      Date or at such time as the Unrestricted Conditions are met or such legend
      is
      otherwise no longer required under this Section 2(e), it will, no later than
      three (3) Trading Days following the delivery (the “Unlegended Shares Delivery
      Deadline”) by the Holder to the Company or the Company’s transfer agent of a
      certificate representing Exercise Shares, as applicable, issued with a
      restrictive legend (such third Trading Day, the “Legend
      Removal Date”),
      deliver or cause to be delivered to such Holder a certificate (or electronic
      transfer) representing such shares that is free from all restrictive and other
      legends. 

    

    (iii)  Sale
      of Unlegended Shares.
      Holder
      agrees that the removal of the restrictive legend from certificates representing
      Securities as set forth in this Section 2(e)(i) above is predicated upon the
      Company’s reliance that the Holder will sell any Exercise Shares pursuant to
      either the registration requirements of the Securities Act, including any
      applicable prospectus delivery requirements, or an exemption therefrom, and
      that
      if Securities are sold pursuant to a Registration Statement, they will be sold
      in compliance with the plan of distribution set forth therein. 

    

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

       

    

    (f)
      Cancellation of Warrant. This
      Warrant shall be canceled upon the full Exercise of this Warrant, and, as soon
      as practical after the Date of Exercise, Holder shall be entitled to receive
      Common Stock for the number of shares purchased upon such Exercise of this
      Warrant, and if this Warrant is not exercised in full, Holder shall be entitled
      to receive a new Warrant (containing terms identical to this Warrant)
      representing any unexercised portion of this Warrant in addition to such Common
      Stock. 

    

    (g)
      Holder of Record. Each
      person in whose name any Warrant for shares of Common Stock is issued shall,
      for
      all purposes, be deemed to be the Holder of record of such shares on the Date
      of
      Exercise of this Warrant, irrespective of the date of delivery of the Common
      Stock purchased upon the Exercise of this Warrant. Nothing in this Warrant
      shall
      be construed as conferring upon Holder any rights as a stockholder of the
      Company.

    

    (h) Delivery
      Of Electronic Shares.
      In lieu
      of delivering physical certificates representing the Common Stock issuable
      upon
      exercise or legend removal, provided the Company’s Transfer Agent is
      participating in the Depository Trust Company ("DTC") Fast Automated Securities
      Transfer ("FAST") program, upon written request of the Holder, the Company
      shall
      use its best efforts to cause its Transfer Agent to electronically transmit
      the
      Common Stock issuable upon exercise to the Holder by crediting the account
      of
      the Holder's Prime Broker with DTC through its Deposit Withdrawal Agent
      Commission ("DWAC") system. The time periods for delivery and penalties
      described herein shall apply to the electronic transmittals described
      herein.

    

    (i)
      Buy-In.
      In
      addition to any other rights available to the Holder, if the Company fails
      to
      cause its transfer agent to transmit to the Holder a certificate or certificates
      representing the Exercise Shares pursuant to an exercise on or before the
      Warrant Share Delivery Date, and if after such date the Holder is required
      by
      its broker to purchase (in an open market transaction or otherwise) or the
      Holder’s brokerage firm otherwise purchases shares of Common Stock to deliver in
      satisfaction of a sale by the Holder of the Exercise Shares which the Holder
      anticipated receiving upon such exercise (a “Buy-In”),
      then
      the Company shall (1) pay in cash to the Holder the amount by which (x) the
      Holder’s total purchase price (including brokerage commissions, if any) for the
      shares of Common Stock so purchased exceeds (y) the amount obtained by
      multiplying (A) the number of Exercise Shares that the Company was required
      to
      deliver to the Holder in connection with the exercise at issue times (B) the
      price at which the sell order giving rise to such purchase obligation was
      executed, and (2) at the option of the Holder, either reinstate the portion
      of
      the Warrant and equivalent number of Exercise Shares for which such exercise
      was
      not honored or deliver to the Holder the number of shares of Common Stock that
      would have been issued had the Company timely complied with its exercise and
      delivery obligations hereunder. For example, if the Holder purchases Common
      Stock having a total purchase price of $11,000 to cover a Buy-In with respect
      to
      an attempted exercise of shares of Common Stock with an aggregate sale price
      giving rise to such purchase obligation of $10,000, under clause (1) of the
      immediately preceding sentence the Company shall be required to pay the Holder
      $1,000. The Holder shall provide the Company written notice indicating the
      amounts payable to the Holder in respect of the Buy-In, together with applicable
      confirmations and other evidence reasonably requested by the Company. Nothing
      herein shall limit a Holder’s right to pursue any other remedies available to it
      hereunder, at law or in equity including, without limitation, a decree of
      specific performance and/or injunctive relief with respect to the Company’s
      failure to timely deliver certificates representing shares of Common Stock
      upon
      exercise of the Warrant as required pursuant to the terms hereof.

    

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

       

    

    3. Payment
      of Warrant Exercise Price.

    

    (a)
      Exercise Price.
      The
      Exercise Price (“Exercise Price”) shall initially equal $1.00
      per
      share (the “Initial Exercise Price”), subject to adjustment pursuant to the
      terms hereof, including but not limited to Section 5 below. 

    

    Payment
      of the Exercise Price may be made by either of the following, or a combination
      thereof, at the election of Holder:

    

    (i) Cash
      Exercise: cash,
      bank or cashiers check or wire transfer (a “Cash Exercise”); or

    

    (ii) Cashless
      Exercise: surrender
      of this Warrant at the principal office of the Company together with notice
      of
      cashless election, in which event the Company shall issue Holder a number of
      shares of Common Stock computed using the following formula (a “Cashless
      Exercise”):

    

    X
      = Y
      (A-B)/A

    

    where: X
      = the
      number of shares of Common Stock to be issued to Holder.

    

    Y
      = the
      number of shares of Common Stock for which this Warrant is being exercised.

    

    A
      = the
      Market Price of one (1) share of Common Stock (for purposes of this Section
      3(ii), where "MARKET PRICE," as of any date, means the Volume Weighted Average
      Price (as defined herein) of the Company’s Common Stock during the five (5)
      consecutive trading day period immediately preceding the date in
      question.

    

    B
      = the
      Exercise Price.

    

    As
      used
      herein, the "VOLUME WEIGHTED AVERAGE PRICE" for any security as of any date
      means the volume weighted average sale price on the Over the Counter Electronic
      Bulletin Board (the “OTC-BB”) as reported by, or based upon data reported by,
      Bloomberg Financial Markets or an equivalent, reliable reporting service
      mutually acceptable to and hereafter designated by holders of a majority in
      interest of the Warrants and the Company ("BLOOMBERG") or, if the OTC-BB is
      not
      the principal trading market for such security, the volume weighted average
      sale
      price of such security on the principal securities exchange or trading market
      where such security is listed or traded as reported by Bloomberg, or, if no
      volume weighted average sale price is reported for such security, then the
      last
      closing trade price of such security as reported by Bloomberg, or, if no last
      closing trade price is reported for such security by Bloomberg, the average
      of
      the bid prices of any market makers for such security that are listed in the
      "pink sheets" by the National Quotation Bureau, Inc. If the Volume Weighted
      Average Price cannot be calculated for such security on such date in the manner
      provided above, the volume weighted average price shall be the fair market
      value
      as mutually determined by the Company and the holders of a majority in interest
      of the Warrants being exercised for which the calculation of the volume weighted
      average price is required in order to determine the Exercise Price of such
      Warrants. "TRADING DAY" shall mean any day on which the Common Sock is traded
      for any period on the OTC-BB, or on the principal securities exchange or other
      securities market on which the Common Stock is then being traded. 

    

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

       

    

    For
      purposes of Rule 144 and sub-section (d)(3)(ii) thereof, it is intended,
      understood and acknowledged that the Common Stock issuable upon exercise of
      this
      Warrant in a cashless exercise transaction shall be deemed to have been acquired
      at the time this Warrant was issued. Moreover, it is intended, understood and
      acknowledged that the holding period for the Common Stock issuable upon exercise
      of this Warrant in a cashless exercise transaction shall be deemed to have
      commenced on the date this Warrant was issued. 

    

    (b)
      Dispute
      Resolution.
      In the
      case of a dispute as to the determination of the closing price or the Volume
      Weighted Average Price of the Company’s common stock or the arithmetic
      calculation of the Exercise Price, Market Price or any Redemption Price, the
      Company shall submit the disputed determinations or arithmetic calculations
      via
      facsimile within two (2) Business Days of receipt, or deemed receipt, of the
      Exercise Notice or Redemption Notice or other event giving rise to such dispute,
      as the case may be, to the Holder. If the Holder and the Company are unable
      to
      agree upon such determination or calculation within two (2) Business Days of
      such disputed determination or arithmetic calculation being submitted to the
      Holder, then the Company shall, within two (2) Business Days
      submit via facsimile (a) the disputed determination of the closing price or
      the
      Volume Weighted Average Price of the Company’s common stock to an independent,
      reputable investment bank selected by the Company and approved by the Holder
      or
      (b) the disputed arithmetic calculation of the Exercise Price, Market Price
      or
      any Redemption Price to the Company’s independent, outside accountant. The
      Company, at the Company’s expense, shall cause the investment bank or the
      accountant, as the case may be, to perform the determinations or calculations
      and notify the Company and the Holder of the results no later than five (5)
      Business Days from the time it receives the disputed determinations or
      calculations. Such investment bank’s or accountant’s determination or
      calculation, as the case may be, shall be binding upon all parties absent
      demonstrable error.

    

    4. Transfer
      and Registration.

    

    (a)
      Transfer
      Rights. Subject
      to the provisions of Section 8 of this Warrant, this Warrant may be transferred
      on the books of the Company, in whole or in part, in person or by attorney,
      upon
      surrender of this Warrant properly completed and endorsed. This Warrant shall
      be
      canceled upon such surrender and, as soon as practicable thereafter, the person
      to whom such transfer is made shall be entitled to receive a new Warrant or
      Warrants as to the portion of this Warrant transferred, and Holder shall be
      entitled to receive a new Warrant as to the portion hereof retained.

    

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

       

    

    (b)
      Registrable
      Securities. The
      Common Stock issuable upon the exercise of this Warrant has registration rights
      pursuant to that certain Registration Rights Agreements between the Company
      and
      the Holder dated even herewith.

    

    5. Anti-Dilution
      Adjustments; Additional Adjustments; Purchase Rights.

    

    (a) Participation.
      The
      Holder, as the holder of this Warrant, shall be entitled to receive such
      dividends paid and distributions made to the holders of Common Stock of the
      Company to the same extent as if the Holder had Exercised this Warrant into
      Common Stock (without regard to any limitations on exercise herein or elsewhere
      and without regard to whether or not a sufficient number of shares are
      authorized and reserved to effect any such exercise and issuance) and had held
      such shares of Common Stock on the record date for such dividends and
      distributions. Payments under the preceding sentence shall be made concurrently
      with the dividend or distribution to the holders of Common Stock. 

    

    (b)
       Recapitalization
      or Reclassification. If
      the
      Company shall at any time effect a recapitalization, reclassification or other
      similar transaction of such character that the shares of Common Stock shall
      be
      changed into or become exchangeable for a larger or smaller number of shares,
      then upon the effective date thereof, the number of shares of Common Stock
      which
      Holder shall be entitled to purchase upon Exercise of this Warrant shall be
      increased or decreased, as the case may be, in direct proportion to the increase
      or decrease in the number of shares of Common Stock by reason of such
      recapitalization, reclassification or similar transaction, and the Exercise
      Price shall be, in the case of an increase in the number of shares,
      proportionally decreased and, in the case of decrease in the number of shares,
      proportionally increased. The Company shall give Holder the same notice it
      provides to holders of Common Stock of any transaction described in this Section
      5(b).

    

    (c) Notice
      of Consolidation
      or Merger. In
      the
      event of a Major Transaction (as defined below) is approved in writing by the
      Holder (a “Permissible Major Transaction”) and occurs, then this Warrant shall
      be exerciseable into such class and type of securities or other assets as Holder
      would have received had Holder exercised this Warrant immediately prior to
      such
      Permissible Major Transaction; provided, however, that Company shall provided
      the Holder with at least thirty (30) business days advance notice to Holder
      before effecting any Permissible Major Transaction.

    

    (d) Exercise
      Price Adjusted. As
      used
      in this Warrant, the term "Exercise Price" shall mean the purchase price per
      share specified in Section 3 of this Warrant, until the occurrence of an event
      stated this Section 5 or otherwise set forth in this Warrant, and thereafter
      shall mean said price as adjusted from time to time in accordance with the
      provisions of said subsection. No such adjustment under this Section 5 shall
      be
      made unless such adjustment would change the Exercise Price at the time by
      $.01
      or more; provided, however, that all adjustments not so made shall be deferred
      and made when the aggregate thereof would change the Exercise Price at the
      time
      by $.01 or more. No adjustment made pursuant to any provision of this Section
      5
      shall have the net effect of increasing the Exercise Price in relation to the
      split adjusted and distribution adjusted price of the Common Stock.

    

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

       

    

    (e) Adjustments:
      Additional Shares, Securities or Assets. In
      the
      event that at any time, as a result of an adjustment made pursuant to this
      Section 5 or otherwise, Holder shall, upon Exercise of this Warrant, become
      entitled to receive shares and/or other securities or assets (other than Common
      Stock) then, wherever appropriate, all references herein to shares of Common
      Stock shall be deemed to refer to and include such shares and/or other
      securities or assets; and thereafter the number of such shares and/or other
      securities or assets shall be subject to adjustment from time to time in a
      manner and upon terms as nearly equivalent as practicable to the provisions
      of
      this Section 5. 

    

    (f)
      Adjustment of Exercise Price Due to Share Issuances (MFN).
      So long
      as any of the Warrants are outstanding, if the Company shall issue, sell, or
      grant or agree to issue, sell or grant (A) any shares of Common Stock, (B)
      any
      option, warrant, debt or security that is convertible or exchangeable into
      Common Stock, at a price per share that is less than the Exercise Price in
      effect at the time of such issue (each, a “Dilutive Issuance”), then, and
      thereafter successively upon each such issue, the Exercise Price shall be
      reduced (an “MFN Adjustment”) to such other lower issue price (the “MFN
      Adjustment Price”). For purposes of this adjustment, the issuance of any
      security carrying the right to convert such security into shares of Common
      Stock
      or of any warrant, right or option to purchase Common Stock shall result in
      an
      adjustment to the Exercise Price upon the issuance of the above-described
      security and again upon any adjustment to the Exercise Price of such securities
      (which shall result in an adjustment of the Exercise Price to an effective
      price
      per share equal to the lesser of the existing Exercise Price and the then
      current exercise price of such securities) and upon the issuance of shares
      of
      Common Stock upon exercise of such exercise or purchase rights if such issuance
      is at a price lower than the then applicable Exercise Price (which shall result
      in an adjustment of the Exercise Price to a price equal to the lesser of the
      existing Exercise Price and the issuance price of such shares of Common Stock).

    

    (g)
      [Intentionally Left Blank].

    

    (h)
      Notice
      of Adjustments. Whenever
      the Exercise Price is adjusted pursuant to the terms of this Warrant, the
      Company shall promptly mail to the Holder a notice (a “Exercise Price Adjustment
      Notice”) setting forth the Exercise Price after such adjustment and setting
      forth a statement of the facts requiring such adjustment. The Company shall,
      upon the written request at any time of the Holder, furnish to such Holder
      a
      like Warrant setting forth (i) such adjustment or readjustment, (ii) the
      Exercise Price at the time in effect and (iii) the number of shares of Common
      Stock and the amount, if any, of other securities or property which at the
      time
      would be received upon Exercise of the Warrant. For purposes of clarification,
      whether or not the Corporation provides an Exercise Price Adjustment Notice
      pursuant to this Section 5(h), upon the occurrence of any event that leads
      to an
      adjustment of the Exercise Price, the Holders are entitled to receive a number
      of Exercise Shares based upon the new Exercise Price, as adjusted, for exercises
      occurring on or after the date of such adjustment, regardless of whether a
      Holder accurately refers to the adjusted Exercise Price in the Notice of
      Exercise.

    

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

       

    

    (i)
      Purchase
      Rights.
       In addition to any other adjustments described herein, if at any time the
      Company grants, issues or sells any Options, Convertible Securities or rights
      to
      purchase stock, warrants, securities or other property pro rata to the record
      holders of any class of shares of Common Stock (the "Purchase Rights"), then
      the
      Holder will be entitled to acquire, upon the terms applicable to such Purchase
      Rights, the aggregate Purchase Rights which the Holder could have acquired
      if
      the Holder had held the proportionate number of shares of Common Stock
      acquirable upon complete exercise of this Warrant (without regard to any
      limitations on the exercise of this Warrant) immediately before the date on
      which a record is taken for the grant, issuance or sale of such Purchase Rights,
      or, if no such record is taken, the date as of which the record holders of
      shares of Common Stock are to be determined for the grant, issue or sale of
      such
      Purchase Rights.

    

    6. Fractional
      Interests.

    

    No
      fractional shares or scrip representing fractional shares shall be issuable
      upon
      the Exercise of this Warrant, but on Exercise of this Warrant, Holder may
      purchase only a whole number of shares of Common Stock. If, on Exercise of
      this
      Warrant, Holder would be entitled to a fractional share of Common Stock or
      a
      right to acquire a fractional share of Common Stock, such fractional share
      shall
      be disregarded and the number of shares of Common Stock issuable upon exercise
      shall be the next higher number of shares.

    

    7. Reservation
      of Shares.

    

    From
      and
      after the date hereof, the Company shall at all times reserve for issuance
      such
      number of authorized and unissued shares of Common Stock (or other securities
      substituted therefor as herein above provided) as shall be sufficient for the
      Exercise of this Warrant and payment of the Exercise Price. If at any time
      the
      number of shares of Common Stock authorized and reserved for issuance is below
      the number of shares sufficient for the Exercise of this Warrant (a “Share
      Authorization Failure”)(based on the Exercise Price in effect from time to
      time), the Company will promptly take all corporate action necessary to
      authorize and reserve a sufficient number of shares, including, without
      limitation, calling a special meeting of stockholders to authorize additional
      shares to meet the Company's obligations under this Section 7, in the case
      of an insufficient number of authorized shares, and using its best efforts
      to
      obtain stockholder approval of an increase in such authorized number of shares.
      The Company covenants and agrees that upon the Exercise of this Warrant, all
      shares of Common Stock issuable upon such exercise shall be duly and validly
      issued, fully paid, nonassessable and not subject to preemptive rights, rights
      of first refusal or similar rights of any person or entity.

     

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

    8. Restrictions
      on Transfer.

    

    (a) Registration
      or Exemption Required. This
      Warrant has been issued in a transaction exempt from the registration
      requirements of the Act by virtue of Regulation D and exempt from state
      registration under applicable state laws. The Warrant and the Common Stock
      issuable upon the Exercise of this Warrant may not be pledged, transferred,
      sold
      or assigned except pursuant to an effective registration statement or an
      exemption to the registration requirements of the Act and applicable state
      laws.

    

    (b)
      Assignment.
      If
      Holder
      can provide the Company with reasonably satisfactory evidence that the
      conditions of (a) above regarding registration or exemption have been satisfied,
      Holder may sell, transfer, assign, pledge or otherwise dispose of this Warrant,
      in whole or in part. Holder shall deliver a written notice to Company,
      substantially in the form of the Assignment attached hereto as Exhibit
      B,
      indicating the person or persons to whom the Warrant shall be assigned and
      the
      respective number of warrants to be assigned to each assignee. The Company
      shall
      effect the assignment within ten (10) days, and shall deliver to the assignee(s)
      designated by Holder a Warrant or Warrants of like tenor and terms for the
      appropriate number of shares.

     

    9. Benefits
      of this Warrant.

    

    Nothing
      in this Warrant shall be construed to confer upon any person other than the
      Company and Holder any legal or equitable right, remedy or claim under this
      Warrant and this Warrant shall be for the sole and exclusive benefit of the
      Company and Holder.

    

    10. Arbitration;
      Governing Law. 

    

    This
      Agreement shall be governed by and construed in accordance with the laws of
      the
      State of New York applicable to agreements made in and wholly to be performed
      in
      that jurisdiction, except for matters arising under the Act or the Securities
      Exchange Act of 1934, which matters shall be construed and interpreted in
      accordance with such laws. Any controversy or claim arising out of or related
      to
      the this Agreement or the breach thereof, shall be settled by binding
      arbitration in New York, New York in accordance with the Expedited Procedures
      (Rules 53-57) of the Commercial Arbitration Rules of the American Arbitration
      Association (“AAA”). A proceeding shall be commenced upon written demand by
      Company or any Lender to the other. The arbitrator(s) shall enter a judgment
      by
      default against any party, which fails or refuses to appear in any properly
      noticed arbitration proceeding. The proceeding shall be conducted by one (1)
      arbitrator, unless the amount alleged to be in dispute exceeds two hundred
      fifty
      thousand dollars ($250,000), in which case three (3) arbitrators shall preside.
      The arbitrator(s) will be chosen by the parties from a list provided by the
      AAA,
      and if they are unable to agree within ten (10) days, the AAA shall select
      the
      arbitrator(s). The arbitrators must be experts in securities law and financial
      transactions. The arbitrators shall assess costs and expenses of the
      arbitration, including all attorneys’ and experts’ fees, as the arbitrators
      believe is appropriate in light of the merits of the parties’ respective
      positions in the issues in dispute. Each party submits irrevocably to the
      jurisdiction of any state court sitting in New York, New York or to the United
      States District Court sitting in New York, New York for purposes of enforcement
      of any discovery order, judgment or award in connection with such arbitration.
      The award of the arbitrator(s) shall be final and binding upon the parties
      and
      may be enforced in any court having jurisdiction. The arbitration shall be
      held
      in such place as set by the arbitrator(s) in accordance with Rule 55. With
      respect to any arbitration proceeding in accordance with this section, the
      prevailing party’s reasonable attorney’s fees and expenses shall be borne by the
      non-prevailing party.

    

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

       

    

    Although
      the parties, as expressed above, agree that all claims, including claims that
      are equitable in nature, for example specific performance, shall initially
      be
      prosecuted in the binding arbitration procedure outlined above, if the
      arbitration panel dismisses or otherwise fails to entertain any or all of the
      equitable claims asserted by reason of the fact that it lacks jurisdiction,
      power and/or authority to consider such claims and/or direct the remedy
      requested, then, in only that event, will the parties have the right to initiate
      litigation respecting such equitable claims or remedies. The forum for such
      equitable relief shall be in either a state or federal court sitting in
New
      York,
      New York.
      Each
      party waives any right to a trial by jury, assuming such right exists in an
      equitable proceeding, and irrevocably submits to the jurisdiction of said New
      Yrok court. New York law shall govern both the proceeding as well as the
      interpretation and construction of this Agreement and the transaction as a
      whole.

    

    11. Loss
      of Warrant.

    

    Upon
      receipt by the Company of evidence of the loss, theft, destruction or mutilation
      of this Warrant, and (in the case of loss, theft or destruction) of indemnity
      or
      security reasonably satisfactory to the Company, and upon surrender and
      cancellation of this Warrant, if mutilated, the Company shall execute and
      deliver a new Warrant of like tenor and date.

    

    12. Notice
      or Demands.

    

    Notices
      or demands pursuant to this Warrant to be given or made by Holder to or on
      the
      Company shall be sufficiently given or made if sent by certified or registered
      mail, return receipt requested, postage prepaid, and addressed, until another
      address is designated in writing by the Company, to the address set forth in
      Section 2(a) above. Notices or demands pursuant to this Warrant to be given
      or
      made by the Company to or on Holder shall be sufficiently given or made if
      sent
      by certified or registered mail, return receipt requested, postage prepaid,
      and
      addressed, to the address of Holder set forth in the Company’s records, until
      another address is designated in writing by Holder.

    

    IN
      WITNESS WHEREOF, the undersigned has executed this Warrant as of the
 ___th
      day of
      April __, 2008.

    
      
        	 	 
	 	 
	 	
                BIOMETRX,
                  INC.

              
	 	 
	 	 
	 	
                By:
                  ________________________

              
	 	
                Print
                  Name: __________________

              
	 	
                Title:
                  ________________________

              
	 	
                         
                  ____________

              

      

    

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

       

    

    EXHIBIT
      A

    

    EXERCISE
      FORM FOR WARRANT

    

    TO:
      BIOMETRX,
      INC.

    

    The
      undersigned hereby irrevocably exercises the right to purchase ____________
      of
      the shares of Common Stock (the “Common Stock”) of BIOMETRX,
      INC.,
      a
      Delaware corporation
      (the
“Company”), evidenced by the attached warrant (the “Warrant”), and herewith
      makes payment of the exercise price with respect to such shares in full, all
      in
      accordance with the conditions and provisions of said Warrant.

    

    1.
      The
      undersigned agrees not to offer, sell, transfer or otherwise dispose of any
      of
      the Common Stock obtained on exercise of the Warrant, except in accordance
      with
      the provisions of Section 8(a) of the Warrant.

    

    2.
      The
      undersigned requests that stock certificates for such shares be issued free
      of
      any restrictive legend, if appropriate, and a warrant representing any
      unexercised portion hereof be issued, pursuant to the Warrant in the name of
      the
      undersigned and delivered to the undersigned at the address set forth
      below:

    

    Dated:________

    

      
        	           
                 
	
                Signature

              
	 
	            
                
	
                Print
                  Name

              
	 
	         

	
                Address

              
	 
	         
                

      

    

     

    NOTICE

    

    The
      signature to the foregoing Exercise Form must correspond to the name as written
      upon the face of the attached Warrant in every particular, without alteration
      or
      enlargement or any change whatsoever.

     

    
      	       

    

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

       

    

    EXHIBIT
      B

    

    ASSIGNMENT

    

    (To
      be
      executed by the registered holder

    desiring
      to transfer the Warrant)

    

    FOR
      VALUE
      RECEIVED, the undersigned holder of the attached warrant (the “Warrant”) hereby
      sells, assigns and transfers unto the person or persons below named the right
      to
      purchase _______ shares of the Common Stock of BIOMETRX,
      INC.,
      a
      Delaware corporation, evidenced
      by the attached Warrant and does hereby irrevocably constitute and appoint
      _______________________ attorney to transfer the said Warrant on the books
      of
      the Company, with full power of substitution in the premises.

     

    
      
        	 	 	 
	
                Dated:

              	
                _________

              	
                ______________________________

              
	 	 	
                Signature

              

      

       

    

    Fill
      in
      for new registration of Warrant:

    

    ___________________________________

    Name

    

    ___________________________________

    Address

    

    ___________________________________

    Please
      print name and address of assignee

    (including
      zip code number)

    

    
      
        

      

       

    

    NOTICE

    

    The
      signature to the foregoing Assignment must correspond to the name as written
      upon the face of the attached Warrant in every particular, without alteration
      or
      enlargement or any change whatsoever.

    

      
        

      

       

    

    
      
        
        

      

      
        14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]